Rallybio (RLYB) Competitors $0.99 +0.03 (+3.11%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends RLYB vs. MGTA, CTMX, OGI, ELDN, CKPT, BDTX, NLTX, IVA, ABOS, and ELUTShould you be buying Rallybio stock or one of its competitors? The main competitors of Rallybio include Magenta Therapeutics (MGTA), CytomX Therapeutics (CTMX), Organigram (OGI), Eledon Pharmaceuticals (ELDN), Checkpoint Therapeutics (CKPT), Black Diamond Therapeutics (BDTX), Neoleukin Therapeutics (NLTX), Inventiva (IVA), Acumen Pharmaceuticals (ABOS), and Elutia (ELUT). These companies are all part of the "medical" sector. Rallybio vs. Magenta Therapeutics CytomX Therapeutics Organigram Eledon Pharmaceuticals Checkpoint Therapeutics Black Diamond Therapeutics Neoleukin Therapeutics Inventiva Acumen Pharmaceuticals Elutia Rallybio (NASDAQ:RLYB) and Magenta Therapeutics (NASDAQ:MGTA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, community ranking, profitability, valuation, risk, earnings, media sentiment and dividends. Do institutionals & insiders have more ownership in RLYB or MGTA? 90.3% of Rallybio shares are held by institutional investors. Comparatively, 47.5% of Magenta Therapeutics shares are held by institutional investors. 7.4% of Rallybio shares are held by insiders. Comparatively, 15.2% of Magenta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more risk & volatility, RLYB or MGTA? Rallybio has a beta of -1.67, suggesting that its share price is 267% less volatile than the S&P 500. Comparatively, Magenta Therapeutics has a beta of 2.12, suggesting that its share price is 112% more volatile than the S&P 500. Do analysts prefer RLYB or MGTA? Rallybio currently has a consensus price target of $9.75, indicating a potential upside of 880.79%. Given Rallybio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Rallybio is more favorable than Magenta Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rallybio 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67Magenta Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in RLYB or MGTA? Magenta Therapeutics received 118 more outperform votes than Rallybio when rated by MarketBeat users. However, 76.47% of users gave Rallybio an outperform vote while only 57.09% of users gave Magenta Therapeutics an outperform vote. CompanyUnderperformOutperformRallybioOutperform Votes3976.47% Underperform Votes1223.53% Magenta TherapeuticsOutperform Votes15757.09% Underperform Votes11842.91% Does the media prefer RLYB or MGTA? In the previous week, Magenta Therapeutics had 1 more articles in the media than Rallybio. MarketBeat recorded 1 mentions for Magenta Therapeutics and 0 mentions for Rallybio. Magenta Therapeutics' average media sentiment score of 0.95 beat Rallybio's score of 0.00 indicating that Magenta Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Rallybio Neutral Magenta Therapeutics Positive Which has higher earnings and valuation, RLYB or MGTA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRallybioN/AN/A-$74.56M-$1.60-0.62Magenta TherapeuticsN/AN/A-$76.46MN/AN/A Is RLYB or MGTA more profitable? Magenta Therapeutics' return on equity of -70.88% beat Rallybio's return on equity.Company Net Margins Return on Equity Return on Assets RallybioN/A -77.39% -69.33% Magenta Therapeutics N/A -70.88%-57.27% SummaryMagenta Therapeutics beats Rallybio on 7 of the 13 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Rallybio News Delivered to You Automatically Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLYB vs. The Competition Export to ExcelMetricRallybioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.85M$6.48B$5.07B$8.89BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-0.624.4283.5712.93Price / SalesN/A375.031,220.3088.33Price / CashN/A52.5939.4636.25Price / Book0.5810.126.936.25Net Income-$74.56M$153.61M$119.12M$225.93M7 Day Performance-1.57%-2.00%-1.83%-1.32%1 Month Performance-9.63%-7.47%-3.64%0.60%1 Year Performance-58.58%31.80%31.64%26.23% Rallybio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLYBRallybio2.5309 of 5 stars$0.99+3.1%$9.75+880.8%-59.4%$39.85MN/A-0.6240MGTAMagenta Therapeutics0.8555 of 5 stars$0.70-7.7%N/A+0.0%$42.44MN/A0.0067Gap DownCTMXCytomX Therapeutics4.3795 of 5 stars$0.87-2.2%$5.77+563.4%-37.4%$69.86M$101.21M5.12170Short Interest ↓OGIOrganigram0.469 of 5 stars$1.48+2.1%N/A+16.5%$157.93M$120.01M-3.52860ELDNEledon Pharmaceuticals2.9405 of 5 stars$3.85-0.8%$16.00+315.6%+210.5%$153.86MN/A0.0010Analyst ForecastAnalyst RevisionCKPTCheckpoint Therapeutics3.4927 of 5 stars$3.38flat$12.00+255.0%+62.5%$152.16M$100,000.000.0010Analyst RevisionBDTXBlack Diamond Therapeutics2.8436 of 5 stars$2.43-4.7%$15.50+537.9%+8.0%$144.29MN/A0.0090Positive NewsNLTXNeoleukin TherapeuticsN/A$15.33-11.0%N/A+30.5%$144.07MN/A-4.9390High Trading VolumeIVAInventiva3.0751 of 5 stars$2.74flat$14.00+410.9%-31.9%$143.79M$18.91M0.00100News CoverageABOSAcumen Pharmaceuticals2.6635 of 5 stars$2.37-0.8%$9.00+279.7%+0.4%$143.59MN/A0.0051Analyst RevisionELUTElutia2.685 of 5 stars$4.38+4.0%$10.00+128.3%+170.4%$143.39M$24.75M0.00180 Related Companies and Tools Related Companies Magenta Therapeutics Alternatives CytomX Therapeutics Alternatives Organigram Alternatives Eledon Pharmaceuticals Alternatives Checkpoint Therapeutics Alternatives Black Diamond Therapeutics Alternatives Neoleukin Therapeutics Alternatives Inventiva Alternatives Acumen Pharmaceuticals Alternatives Elutia Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RLYB) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rallybio Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rallybio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RLYB Stock Alerts